Thomas W LeBlanc1,2, Myles Nickolich3, Christel N Rushing4, Gregory P Samsa4, Susan C Locke5, Amy P Abernethy5. 1. Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA. thomas.leblanc@duke.edu. 2. Center for Learning Health Care, Duke Clinical Research Institute, Durham, NC, USA. thomas.leblanc@duke.edu. 3. Department of Medicine, Duke University Medical Center, Durham, NC, USA. 4. Department of Bioinformatics and Biostatistics, Duke University Medical Center, 2400 Pratt Street, Suite 9000, Durham, NC, 27705, USA. 5. Center for Learning Health Care, Duke Clinical Research Institute, Durham, NC, USA.
Abstract
PURPOSE: Patients with advanced non-small cell lung cancer (aNSCLC) face a significant symptom burden. Little is known about the frequency and severity of symptoms over time, so we longitudinally characterized patients' symptoms using the Patient Care Monitor (PCM) version 2.0, an electronic symptom-assessment tool. METHODS: Ninety-seven patients with aNSCLC completed the PCM at up to four clinic visits. We analyzed symptom data by incidence, severity, type (functional vs. nonfunctional), proximity to death, and cancer anorexia-cachexia syndrome status (CACS). RESULTS: Functional concerns predominated, even in the non-CACS group. Average severity among the top 5 symptoms was worse for functional than nonfunctional items (mean difference 0.62, 95% CI 0.22-1.01, P = 0.003). Severe dyspnea and fatigue were the most prevalent nonfunctional symptoms; moderate/severe dyspnea was reported by at least 29% of patients, and fatigue by over 50%. Depression was reported infrequently, with over half of patients at each visit reporting "none"; moderate or severe depression was reported in only 2.5-9.3 and 3.4-6.2% of patients, respectively. The average number of moderate/severe symptoms increased with proximity to death; 84% reported moderate/severe fatigue in the last 3 months of life, compared to 48% at ≥ 12 months from death (P = 0.007). CONCLUSIONS: Patients with aNSCLC face a significant symptom burden, which increases with proximity to death. Symptom type and severity vary by proximity to death, but even patients without overt CACS report significant functional symptoms throughout. We recommend an individualized approach to palliative symptom intervention in advanced lung cancer, based on detailed symptom assessment and tracking.
PURPOSE:Patients with advanced non-small cell lung cancer (aNSCLC) face a significant symptom burden. Little is known about the frequency and severity of symptoms over time, so we longitudinally characterized patients' symptoms using the Patient Care Monitor (PCM) version 2.0, an electronic symptom-assessment tool. METHODS: Ninety-seven patients with aNSCLC completed the PCM at up to four clinic visits. We analyzed symptom data by incidence, severity, type (functional vs. nonfunctional), proximity to death, and cancer anorexia-cachexia syndrome status (CACS). RESULTS: Functional concerns predominated, even in the non-CACS group. Average severity among the top 5 symptoms was worse for functional than nonfunctional items (mean difference 0.62, 95% CI 0.22-1.01, P = 0.003). Severe dyspnea and fatigue were the most prevalent nonfunctional symptoms; moderate/severe dyspnea was reported by at least 29% of patients, and fatigue by over 50%. Depression was reported infrequently, with over half of patients at each visit reporting "none"; moderate or severe depression was reported in only 2.5-9.3 and 3.4-6.2% of patients, respectively. The average number of moderate/severe symptoms increased with proximity to death; 84% reported moderate/severe fatigue in the last 3 months of life, compared to 48% at ≥ 12 months from death (P = 0.007). CONCLUSIONS:Patients with aNSCLC face a significant symptom burden, which increases with proximity to death. Symptom type and severity vary by proximity to death, but even patients without overt CACS report significant functional symptoms throughout. We recommend an individualized approach to palliative symptom intervention in advanced lung cancer, based on detailed symptom assessment and tracking.
Authors: Jaclyn Yoong; Elyse R Park; Joseph A Greer; Vicki A Jackson; Emily R Gallagher; William F Pirl; Anthony L Back; Jennifer S Temel Journal: JAMA Intern Med Date: 2013-02-25 Impact factor: 21.873
Authors: Ping Yang; Andrea L Cheville; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Matthew M Clark; Stephen D Cassivi; David E Midthun; Randolph S Marks; Marie-Christine Aubry; Scott H Okuno; Brent A Williams; Francis C Nichols; Victor F Trastek; Hiroshi Sugimura; Linda Sarna; Mark S Allen; Claude Deschamps; Jeff A Sloan Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: Amy P Abernethy; James E Herndon; Jane L Wheeler; Jeannette M Day; Linda Hood; Meenal Patwardhan; Heather Shaw; Herbert Kim Lyerly Journal: J Pain Symptom Manage Date: 2009-04-25 Impact factor: 3.612
Authors: Ilse A van den Dungen; Constans A Verhagen; Winette T van der Graaf; Jan-Paul van den Berg; Kris C Vissers; Yvonne Engels Journal: J Palliat Med Date: 2014-07-08 Impact factor: 2.947
Authors: O P Geerse; D Brandenbarg; H A M Kerstjens; A J Berendsen; S F A Duijts; H Burger; G A Holtman; J E H M Hoekstra-Weebers; T J N Hiltermann Journal: Lung Cancer Date: 2019-02-10 Impact factor: 5.705
Authors: Seyyed Mohammad Reza Kazemi-Bajestani; Harald Becher; Charles Butts; Naveen S Basappa; Michael Smylie; Anil Abraham Joy; Randeep Sangha; Andrea Gallivan; Quincy Chu; Vickie E Baracos Journal: Support Care Cancer Date: 2018-12-13 Impact factor: 3.603
Authors: Melisa L Wong; Steven M Paul; Bruce A Cooper; Laura B Dunn; Marilyn J Hammer; Yvette P Conley; Fay Wright; Jon D Levine; Louise C Walter; Frances Cartwright; Christine Miaskowski Journal: Support Care Cancer Date: 2017-02-03 Impact factor: 3.603
Authors: Fiona Blackhall; D Ross Camidge; Alice T Shaw; Jean-Charles Soria; Benjamin J Solomon; Tony Mok; Vera Hirsh; Pasi A Jänne; Yuankai Shi; Pan-Chyr Yang; Tommaso De Pas; Toyoaki Hida; Javier De Castro Carpeño; Silvana Lanzalone; Anna Polli; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Dong-Wan Kim Journal: ESMO Open Date: 2017-08-17